Skip to main content

Table 1 Patient characteristics

From: Predictive value of quantitative 18F-FDG-PET radiomics analysis in patients with head and neck squamous cell carcinoma

  Training cohort Validation cohort
  Number (%) Number (%)
Patients total 103 71
No of male patients 76 (73.8%) 53 (75.7%)
Age, years (mean, IQR) 62.3 (57.3–67.8) 63.3 (57.8–69.3)
Mean radiation dose, Gy 70 70
Chemotherapy
 Cisplatin 88 (85.4%) 57 (80%)
 Cetuximab 15 (14.6%) 14 (20%)
T-stage
 2 46 (44.7%) 25 (35.2%)
 3 24 (23.3%) 19 (26.8%)
 4 33 (32%) 27 (38%)
N-stage
 0 14 (13.6%) 11 (15.5%)
 1 13 (12.6%) 15 (21.1%)
 2 75 (72.8%) 45 (63.4%)
 3 1 (1%) 0 (0%)
HPV-status
 Positive 39 (37.9%) 26 (36.6%)
 Negative 64 (62.1%) 45 (63.4%)
Tumor site
 Oropharynx 74 (71.8%) 51 (71.8%)
 Hypopharynx 29 (28.2%) 20 (28.2%)
Overall alcohol history score (SD) 1.91 (1.19) 1.72 (1.24)
Smoking pack years, (IQR) 22.7 (18.2–38.9) 23.5 (19.3–41.3)
Follow-up time (mean, IQR) 31.5 (20.7–44.5) 26.4 (19.8–34.1)
Recurrence 27 (26.2%) 19 (27.1%)
Metastasis 10 (9.7%) 18 (25.7%)
Death 37 (35.9%) 22 (31.4%)
IQR: interquartile range